Exelixis, Inc. 10-Q Summary: Quarter Ended September 30, 2004
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2004, for Exelixis, Inc., a biotechnology company focused on drug discovery and development for cancer, metabolism, and other serious diseases. The company operates primarily through internal research and development and strategic collaborations with pharmaceutical and agrochemical partners. As of October 25, 2004, there were 74,812,073 shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2004 | Nine Months Ended Sep 30, 2004 | Balance Sheet (Sep 30, 2004) |
|---|---|---|---|
| Total Revenues | $12,662 | $37,113 | - |
| Net Loss | $(27,189) | $(85,323) | - |
| Net Loss Per Share (Basic/Diluted) | $(0.38) | $(1.19) | - |
| Cash and Cash Equivalents | - | - | $47,993 |
| Short-term Investments | - | - | $82,851 |
| Total Current Assets | - | - | $142,466 |
| Total Current Liabilities | - | - | $42,168 |
| Working Capital | - | - | $100,298 |
| Long-term Debt (Notes & Convertible) | - | - | $102,791 |
| Accumulated Deficit | - | - | $(467,451) |
Note: The company reported a net cash decrease of $63.8 million for the nine-month period, driven primarily by operating losses.
Material Changes vs. Prior Period
- Revenue: Total revenue increased slightly by 2% ($0.2 million) for the three months ended September 30, 2004, compared to the prior year, driven by increased contract revenues and a milestone payment from Bristol-Myers Squibb. However, for the nine-month period, revenue decreased by 2% ($0.7 million) due to the conclusion of the Protein Design Labs collaboration and the full amortization of upfront payments from Bristol-Myers Squibb.
- Expenses: Research and Development (R&D) expenses increased by 5% ($1.8 million) for the quarter and 8% ($7.6 million) for the nine months. This increase was primarily due to higher consulting and professional fees associated with advancing clinical trials (XL119, XL647, XL999) and facility expansion.
- Restructuring: The company recorded a restructuring charge of $2.3 million for the nine months ended September 30, 2004, compared to $0.6 million in the prior year period. This included a $1.7 million charge in Q2 2004 for a reduction in force of 62 employees.
- Liquidity: Cash and cash equivalents decreased from $111.8 million at December 31, 2003, to $48.0 million at September 30, 2004. Total liquid assets (cash, equivalents, and short-term investments) stood at approximately $130.8 million, with an additional $16.4 million in restricted cash.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Management anticipates that current cash, investments, and funding from collaborators will sustain operations for at least the next 15 months. The company expects to continue incurring substantial losses as it advances its pipeline. Future capital requirements will depend on clinical trial progress, regulatory approvals, and the need to expand product development.
Recent Developments:
- X-Ceptor Acquisition: On September 27, 2004, Exelixis entered into a definitive agreement to acquire X-Ceptor Therapeutics, Inc., closing on October 18, 2004. The preliminary purchase price is approximately $25.0 million (stock, cash, and transaction costs). A substantial portion will be recorded as purchased in-process R&D expense in Q4 2004.
- Clinical Pipeline: Phase 3 trials for XL119 (bile duct tumors) are ongoing. Phase 1 trials for XL647 and XL999 have been initiated. The company expects to file IND applications for XL880, XL820, XL844, and XL184 in the first half of 2005.
Risks and Contingencies:
- Financial Covenants: The company must maintain specific financial covenants with lenders (SmithKlineBeecham and GE Capital). As of September 30, 2004, the company was in compliance with an alternative covenant requiring cash and investments of at least $50 million (actual: $147.2 million). Failure to meet these covenants could result in immediate repayment of obligations.
- Collaboration Dependence: A significant portion of revenue is derived from collaborations. Expiration or termination of agreements (e.g., Bristol-Myers Squibb mechanism of action agreement expired in September 2004) could materially impact revenue.
- Regulatory and Clinical Risk: Clinical trials are lengthy and uncertain. Failure to demonstrate safety or efficacy could delay or prevent regulatory approval.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $147.2 million in liquid assets against the projected 15-month operational runway, considering the upcoming $25 million X-Ceptor acquisition costs and potential Q4 R&D charges.
- Debt Covenants: Confirm ongoing compliance with the SmithKlineBeecham loan agreement (cash/investment minimum of $50 million) and GE Capital lease agreement (unrestricted cash minimum of $35 million).
- X-Ceptor Integration: Assess the impact of the X-Ceptor acquisition on the Q4 2004 financials, specifically the non-cash charge for in-process R&D and the dilution from the issuance of 2.5 million shares.
- Clinical Milestones: Monitor the progress of the XL119 Phase 3 trial and the initiation of Phase 1 trials for XL647 and XL999, as these are critical for future revenue generation and valuation.
- Collaboration Renewals: Review the status of expiring collaboration agreements (e.g., Bristol-Myers Squibb, Dow AgroSciences) and the potential for renewal or replacement to sustain revenue streams.